Outcome
    Moderate Evidence

    Vitamin E for Antioxidant Protection

    Vitamin E is a genuine lipid-phase antioxidant in vitro, but supplementation has repeatedly failed to translate to health benefit.

    Overview

    Vitamin E is a genuine lipid-phase antioxidant in vitro, but supplementation has repeatedly failed to translate to health benefit.

    Verdict

    Mixed evidence

    How It Works

    Alpha-tocopherol terminates lipid peroxidation chain reactions in cell membranes and lipoproteins.

    Dosing & Protocol

    Typical dose

    Recommended dose
    Studied at 200-800 IU/day of alpha-tocopherol; marker changes occur but clinical trials were negative or harmful
    Expected timeframe
    Not established

    Protocol

    form
    Mixed tocopherols or food sources - nuts, seeds and vegetable oils - are preferable to high-dose synthetic dl-alpha-tocopherol, which is less bioavailable and displaces gamma-tocopherol
    duration
    Prevention trials ran 3-10 years
    co factor
    Take with a fat-containing meal if supplementing. Evidence is mixed and the clinical record is poor. Vitamin E is the principal lipid-soluble chain-breaking antioxidant in cell membranes and reliably reduces lipid peroxidation markers such as F2-isoprostanes, so the biochemical effect is real. The clinical translation failed repeatedly: the HOPE trial found no cardiovascular benefit and more heart failure, a Miller meta-analysis found increased all-cause mortality above 400 IU/day, and SELECT found 400 IU/day increased prostate cancer incidence by 17%.
    titration
    Do not exceed 1,000 mg/day (about 1,500 IU natural or 1,100 IU synthetic), the tolerable upper intake level; harms have appeared well below this in long trials
    starting dose
    Caution is warranted. Trials used 200-800 IU/day of alpha-tocopherol; the RDA is 15 mg/day, met easily by diet

    Evidence

    What the studies say

    Despite clear biomarker effects, large trials including HOPE and SELECT found no benefit and some harm signals; a meta-analysis linked high-dose vitamin E to increased all-cause mortality.

    Vitamin E and cardiovascular disease prevention

    Score: 6/10
    2004

    Rimm, E.B., Stampfer, M.J.

    Large observational cohorts reported lower coronary heart disease rates among people with high vitamin E intake, but randomised trials of alpha-tocopherol supplementation, including HOPE and GISSI, found no reduction in cardiovascular events. High-dose supplementation showed signals of harm, including increased heart failure and haemorrhagic stroke risk in some trials.

    View source

    Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases

    Score: 9/10
    2012
    meta_analysis
    n=296707

    Bjelakovic G, Nikolova D, Gluud LL +2 more

    Antioxidant supplements did not reduce mortality; beta-carotene and vitamin E were associated with increased mortality

    View source

    Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality

    Score: 9/10
    2005
    meta_analysis
    n=135967

    Miller ER, Pastor-Barriuso R, Dalal D +3 more

    High-dosage vitamin E supplementation (400 IU/day or more) may increase all-cause mortality.

    View source

    Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial

    Score: 10/10
    2008
    rct
    n=14641

    Sesso HD, Buring JE, Christen WG +7 more

    Neither vitamin E nor vitamin C reduced major cardiovascular events in male physicians.

    View source

    Safety

    Caveats

    Vitamin E is the clearest cautionary tale in antioxidant supplementation: the biochemistry works, the clinical outcomes did not, and the harms are real. SELECT found 400 IU/day increased prostate cancer incidence by 17% in healthy men, Miller meta-analysis found increased all-cause mortality above 400 IU/day, and HOPE found increased heart failure. Vitamin E also inhibits platelet aggregation and antagonises vitamin K, meaningfully increasing bleeding risk - it interacts with warfarin, DOACs, aspirin and clopidogrel, has been associated with haemorrhagic stroke, and should be stopped at least two weeks before surgery. High-dose alpha-tocopherol also depletes gamma-tocopherol, which may itself matter. Interactions include reduced efficacy of statins and niacin combinations, and possible interference with chemotherapy and radiotherapy, which act partly through oxidative mechanisms. In pregnancy, high-dose vitamin E is not recommended - trials in pre-eclampsia prevention found no benefit and possible harm. Getting vitamin E from nuts, seeds and vegetable oils carries none of these risks.

    Less likely to help if

    Everyone - the large trials found no benefit and evidence of harm.

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.